Ranger Biotechnologies A/S

CVR 32280404 · Public limited company (A/S) · Active · Medium risk

Ranger Biotechnologies A/S is a Public limited company (A/S), founded on , based in Odense SØ. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 2.3% over the next 12 months, which is 1.6 times the average for Danish companies. 16 annual reports have been published, of which 1 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK 711k and a net result of DKK -843k.

Bankruptcy risk for Ranger Biotechnologies A/S

2.3%
probability of bankruptcy within 12 months
Medium risk

1.6 × the average (1.41%) · higher risk than 84% of active Danish companies

Lowest riskHighest risk

Increases the risk

Return on assets< -20% · bankruptcy rate 16.7%1.9×
Going-concern uncertaintyYes · bankruptcy rate 16.3%1.9×
Moves in the last 2 years1 · bankruptcy rate 12.7%1.4×
Number of CEOs0 · bankruptcy rate 12.7%1.4×
CEOs in total (historical)0 · bankruptcy rate 12.4%1.4×
Website registeredYes · bankruptcy rate 12.0%1.4×
Time at current address< 0.5 yrs · bankruptcy rate 12.0%1.4×
Annual reports filed late1 · bankruptcy rate 11.3%1.3×

Reduces the risk

Auditor's statementExtended review · bankruptcy rate 2.9%0.33×
Published annual reports10+ · bankruptcy rate 3.0%0.35×
Equity ratio60%+ · bankruptcy rate 3.3%0.38×
Current ratio200%–500% · bankruptcy rate 3.4%0.39×
Age (years)10–20 yrs · bankruptcy rate 3.9%0.45×
Company typeA/S · bankruptcy rate 4.4%0.50×
Share of late annual reports0.01%–25% · bankruptcy rate 4.5%0.51×
Number of auditors (historical)2 · bankruptcy rate 4.6%0.52×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
32280404
Status
Active
Company type
Public limited company (A/S)
Founded
(17 years)
Address
C.F. Tietgens Boulevard 30A, kl.
5220 Odense SØ
Municipality
Odense
Industry
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Share capital
DKK 9.4m
Employees
0 (2018)
Auditor
SØNDERJYLLANDS REVISION STATSAUTORISERET REVISIONSAKTIESELSKAB
Audit opted out
No

Warning signs

Annual reports filed late1 of 16
Missing annual reportNo
Negative equityNo
Equity ratio94.1%
Current ratio334%
Moves (last 2 years)1
CEO changes in total0
CEO's previous bankruptcies0
Other companies at the address48
Going-concern uncertaintyYes

Financials and key figures

Financial year20252024
Gross profitDKK -409kDKK -225k
Net profitDKK -843kDKK -1.1m
EquityDKK 711kDKK 1.6m
Total assetsDKK 756kDKK 1.6m
CashDKK 49k–
Short-term debtDKK 44k–
Avg. employees1–

Latest annual report: Reporting class B · auditor's statement: Erklæring om udvidet gennemgang · Sønderjyllands Revision, Statsautoriseret revisionsaktieselskab.

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 2025182
1 Jan 2024 – 31 Dec 2024181
1 Jan 2023 – 31 Dec 2023183
1 Jan 2022 – 31 Dec 2022174
1 Jan 2021 – 31 Dec 2021172
1 Jan 2020 – 31 Dec 2020165
1 Jan 2019 – 31 Dec 2019244 Late
1 Jan 2018 – 31 Dec 2018165
1 Jan 2017 – 31 Dec 2017160
1 Jan 2016 – 31 Dec 201669
1 Jan 2015 – 31 Dec 201564
1 Jan 2014 – 31 Dec 201479
1 Jan 2013 – 31 Dec 2013146
1 Jan 2012 – 31 Dec 2012163
1 Jan 2011 – 31 Dec 2011157
1 Jul 2009 – 31 Dec 2010153

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
BoardHans Thorleif MøllerCurrent
BoardSøren Tvede LarsenCurrent
BoardChristina Møller UdesenCurrent
BoardKasper Tvede LarsenCurrent
BoardPalle Schelde Jensen
BoardFinn Cilius Nielsen
BoardOle Bitsch-Jensen
BoardPeter Buhl
BoardJohn Riis Mortensen
BoardSøren Morgenthaler Echwald
BoardPeter Buhl
BoardJarne Elleholm
Owner (50%)QUERDENKER ApSCurrent
Owner (33%)Outlate Holding ApSCurrent
Owner (67%)4 BEST INVEST ApS
Owner (5%)QUERDENKER ApS
AuditorSØNDERJYLLANDS REVISION STATSAUTORISERET REVISIONSAKTIESELSKABCurrent
AuditorSØNDERJYLLANDS REVISION STATSAUTORISERET REVISIONSAKTIESELSKAB
AuditorEY Godkendt Revisionspartnerselskab
FounderQUERDENKER ApSCurrent

Address history (5 moves)

C.F. Tietgens Boulevard 30A, kl., 5220 Odense SØ
C.F. Tietgens Boulevard 30A, st. th, 5220 Odense SØ
Skovvænget 32, 5792 Årslev
Lysholt Allé 10, 2., 7100 Vejle
Dandyvej 19, 7100 Vejle
c/o Liplasome Pharma A/S, Diplomvej 378, 2800 Kgs. Lyngby

Former names

Ranger Biotechnologies A/S – now
MIRRX THERAPEUTICS A/S –
MIRX THERAPEUTICS A/S –
MIRX THERAPEUTICS ApS –

Employees per year

Number of employees at Ranger Biotechnologies A/S per year232011: 120112012: 120122013: 120132014: 120142015: 120152016: 120162017: 320172018: 02018

Other companies at the same address

Similar companies in Odense

Questions and answers about Ranger Biotechnologies A/S

Has Ranger Biotechnologies A/S gone bankrupt?

No, Ranger Biotechnologies A/S is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of Ranger Biotechnologies A/S?

Our model estimates a bankruptcy risk of 2.3% over the next 12 months (medium risk), which is 1.6 times the average for Danish companies.

Who is the auditor of Ranger Biotechnologies A/S?

Ranger Biotechnologies A/S most recently used SØNDERJYLLANDS REVISION STATSAUTORISERET REVISIONSAKTIESELSKAB.

When was Ranger Biotechnologies A/S founded?

Ranger Biotechnologies A/S was founded on 1 July 2009.

What is the equity of Ranger Biotechnologies A/S?

Equity was DKK 711k according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.